Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076862 · ClinicalTrials.gov registry record · Early Phase 1
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
A Early Phase 1 study of PASC Post Acute Sequelae of COVID 19, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT07076862: Recruiting Early Phase 1 study of PASC Post Acute Sequelae of COVID 19, sponsored by University of California, Davis.
NCT07076862 is a Early Phase 1 study of PASC Post Acute Sequelae of COVID 19 that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 51 participants, below the 224-participant average among 6 other PASC Post Acute Sequelae of COVID 19 trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076862, a Early Phase 1 study of PASC Post Acute Sequelae of COVID 19, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.
Primary Outcome
To assess immune activation in convalescent COVID-19, dynamic PET/CT scans will be analyzed to generate time-activity curves (TACs) in multiple tissues. Kinetic modeling will be applied to extract uptake parameters including SUV, SUVR, Vt, Ki, and k3. These values will be reported and statistically compared between PASC and control participants.
Conditions Studied
Interventions
- DRUG A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)
- DRUG A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
- DRUG B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)
- DRUG B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
Study Locations (2)
California
- UC Davis EXPLORER Molecular Imaging Center - Sacramento
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2029-12 |
| Phase | Early Phase 1 |
What NCT07076862 shows while recruiting
NCT07076862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 224-participant average among 6 other PASC Post Acute Sequelae of COVID 19 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with PASC Post Acute Sequelae of COVID 19 appearing as the primary indexed condition, and to 4 interventions - of which A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) is the first listed.
NCT07076862 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07076862 about?
NCT07076862 is a clinical study titled "Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)". This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and ...
What is the current status of trial NCT07076862?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 51 participants. The study started on 2025-12-04. Estimated completion is 2029-12.
What conditions does trial NCT07076862 study?
This clinical trial studies the following conditions: PASC Post Acute Sequelae of COVID 19.
What interventions are being tested in trial NCT07076862?
The interventions under investigation include: A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) (DRUG), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) (DRUG), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) (DRUG), B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) (DRUG).
Who is sponsoring clinical trial NCT07076862?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076862 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PASC Post Acute Sequelae of COVID 19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2
RECRUITING · NA
-
Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection
RECRUITING
-
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
ACTIVE NOT RECRUITING
-
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
ACTIVE NOT RECRUITING · NA
-
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI